相关实验视频
Updated: May 6, 2026

07:34
FISH for Pre-implantation Genetic Diagnosis
Published on: February 23, 2011
36.7K
对遗传性心血管疾病的基于哈普洛型的植入前遗传测试:一个多学科的方法
Han Liu1,2, Xiao Bao1,2, Hao Shi1,2
1Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450052, Henan, China.
Molecular genetics and genomics : MGG
|December 31, 2024
概括
基于单基性缺陷 (PGT-M) 的 Haplotyping 预植入基因测试有效预防遗传性心血管疾病 (CVD). 这种可靠的方法通过识别无突变的胚胎来确保健康的婴儿,强调了多学科护理的重要性.
科学领域:
- 医学遗传学 医学遗传学
- 生殖医学 生殖医学
- 心脏病学 心脏病学
背景情况:
- 遗传性心血管疾病 (CVD) 由于高发病率,死亡率和遗传因素而带来重大健康风险.
- 预防遗传性心血管疾病的传播对于公共卫生和临床研究至关重要.
研究的目的:
- 评估基于哈普洛类型的单基性缺陷 (PGT-M) 预植入基因测试的可行性和必要性,以预防遗传性心血管疾病.
- 评估PGT-M在鉴定有遗传性心血管疾病史的夫妇中无突变胚胎的有效性.
主要方法:
- 对12个遗传性心血管疾病家族进行了15次PGT-M循环,分析使用卡里映射或单精子下一代测序 (NGS) 的致病基因.
- 采用链接分析来确定胚胎基因型,并查形状.
- 使用产前诊断测试通过羊膜切割进行验证.
主要成果:
- 在分析的120个胚胎中,只有26.7% (32/120) 的胚胎被证实是无突变且是繁体胚胎.
- 十对夫妇成功实现了健康的怀孕,产前诊断证实了PGT-M结果.
- 一个多学科团队 (MDT) 为女性心血管疾病患者提供了必要的支持.
结论:
- 基于哈普洛型的PGT-M是预防遗传性心血管疾病的可靠和必要的策略.
- 多学科合作显著提高了心血管疾病预防和患者管理.
- PGT-M有效地防止遗传性心血管疾病传播给后代.
相关概念视频
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753

